Even though no data are available regarding the role of FAK in DDR, specifically in SCLC, we hypothesize that FAK TKI might also be used in SCLC to improve the efficiency of chemotherapy and/or radiotherapy by impairing DDR and/or increasing DNA damage based on these findings in other cancers. The gene discussed is PTK2; the disease is small cell lung carcinoma.